[Skip to Content]

Upstate Active Clinical Trials

Study Title:

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (CHARM)

What is the purpose of the study?

To determine if BIIB093 improves functional outcome when compared with placebo in participants with Large Hemispheric Infarction (LHI)

Upstate Institutional Review Board (IRB) Number:

1243116

Study/Protocol ID:

252LH301

Study Phase:

Phase 3

Patient Age Group:

Adults

Principal Investigator:

Julius Gene S Latorre

What is involved if I participate?

  • How long is the study?
    12 months
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    ECG, neuroimaging, blood tests, NIHSS, mRS

Where will the study take place?

Upstate Hospital

ClinicalTrials.Gov ID:

NCT02864953

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Lena F Deb
Phone: 315-464-9756
Email: debl@upstate.edu

Return to Previous Page || Search Again

Top